Yvette Dean
New
We are setting up J0741 - Injection, cabotegravir and rilpivirine, 2mg/3mg and this requires two individual gluteal injections. Would you capture 96372 for each injection?
Cabotegravir and rilpivirine, a co-packaged combination of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated for the treatment of HIV-1 infections in adults, ages 18 and older, who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) and are currently on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to cabotegravir or rilpivirine. It is supplied in two single dose kits. The 600 mg/900 mg kit for initial injection doses contains a single dose vial of 600 mg/2 mL (200 mg/mL) cabotegravir and a single dose vial of 900 mg/2 mL (300 mg/mL) rilpivirine. The 400 mg/600 mg kit for continued injections contains a single dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir and a single dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine. Patients should be treated with oral lead-in dosing (30 mg cabotegravir and 25 mg rilpivirine daily) for one month prior to initiating injectable treatment to assess tolerability. Individual intramuscular (IM) gluteal injections, on opposite sides or 2 cm apart, should begin on the last day of oral lead-in dosing and continue once every month thereafter. It must be administered by a health care professional. See full prescribing information for complete administration instructions.
Cabotegravir and rilpivirine, a co-packaged combination of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated for the treatment of HIV-1 infections in adults, ages 18 and older, who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) and are currently on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to cabotegravir or rilpivirine. It is supplied in two single dose kits. The 600 mg/900 mg kit for initial injection doses contains a single dose vial of 600 mg/2 mL (200 mg/mL) cabotegravir and a single dose vial of 900 mg/2 mL (300 mg/mL) rilpivirine. The 400 mg/600 mg kit for continued injections contains a single dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir and a single dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine. Patients should be treated with oral lead-in dosing (30 mg cabotegravir and 25 mg rilpivirine daily) for one month prior to initiating injectable treatment to assess tolerability. Individual intramuscular (IM) gluteal injections, on opposite sides or 2 cm apart, should begin on the last day of oral lead-in dosing and continue once every month thereafter. It must be administered by a health care professional. See full prescribing information for complete administration instructions.